Ontology highlight
ABSTRACT: Background
Optimal parathyroid hormone (PTH) control during non-dialysis chronic kidney disease (ND-CKD) might decrease the subsequent risk of parathyroid hyperplasia and uncontrolled secondary hyperparathyroidism (SHPT) on dialysis. However, the evidence for recommending PTH targets and therapeutic strategies is weak for ND-CKD. We evaluated the patient characteristics, treatment patterns and PTH control over the first year of haemodialysis (HD) by PTH prior to HD initiation.Methods
We studied 5683 incident HD patients from 21 countries in Dialysis Outcomes and Practice Patterns Study Phases 4-6 (2009-18). We stratified by PTH measured immediately prior to HD initiation and reported the monthly prescription prevalence of active vitamin D and calcimimetics over the first year of HD and risk of PTH >600?pg/mL after 9-12?months on HD.Results
The 16% of patients with PTH >600?pg/mL prior to HD initiation were more likely to be prescribed active vitamin D and calcimimetics during the first year of HD. The prevalence of PTH >600?pg/mL 9-12?months after start of HD was greater for patients who initiated HD with PTH >600 (29%) versus 150-300 (7%) pg/mL (adjusted risk difference: 19%; 95% confidence interval : 15%, 23%). The patients with sustained PTH >600?pg/mL after 9-12?months on HD were younger, more likely to be black, and had higher serum phosphorus and estimated glomerular filtration rates at HD initiation.Conclusions
Increased PTH before HD start predicted a higher PTH level 9-12?months later, despite greater use of active vitamin D and calcimimetics. More targeted PTH control during ND-CKD may influence outcomes during HD, raising the need for PTH target guidelines in these patients.
SUBMITTER: Tabibzadeh N
PROVIDER: S-EPMC7771977 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
Tabibzadeh Nahid N Karaboyas Angelo A Robinson Bruce M BM Csomor Philipp A PA Spiegel David M DM Evenepoel Pieter P Jacobson Stefan H SH Ureña-Torres Pablo-Antonio PA Fukagawa Masafumi M Al Salmi Issa I Liang Xinling X Pisoni Ronald L RL Young Eric W EW
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20210101 1
<h4>Background</h4>Optimal parathyroid hormone (PTH) control during non-dialysis chronic kidney disease (ND-CKD) might decrease the subsequent risk of parathyroid hyperplasia and uncontrolled secondary hyperparathyroidism (SHPT) on dialysis. However, the evidence for recommending PTH targets and therapeutic strategies is weak for ND-CKD. We evaluated the patient characteristics, treatment patterns and PTH control over the first year of haemodialysis (HD) by PTH prior to HD initiation.<h4>Methods ...[more]